Traws Pharma Croissance future
Future contrôle des critères 0/6
Traws Pharma is forecast to grow revenue at 1% per annum. EPS is expected to grow by 76.3% per annum.
Informations clés
n/a
Taux de croissance des bénéfices
76.3%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 18.0% |
| Taux de croissance des recettes | 1.0% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 09 Oct 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 0 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 0 | N/A | N/A | N/A | 1 |
| 6/30/2024 | 0 | -137 | -23 | -23 | N/A |
| 3/31/2024 | 0 | -18 | -18 | -18 | N/A |
| 12/31/2023 | 0 | -19 | -18 | -18 | N/A |
| 9/30/2023 | 0 | -20 | -17 | -17 | N/A |
| 6/30/2023 | 0 | -21 | -17 | -17 | N/A |
| 3/31/2023 | 0 | -21 | -17 | -17 | N/A |
| 12/31/2022 | 0 | -19 | -16 | -16 | N/A |
| 9/30/2022 | 0 | -17 | -17 | -17 | N/A |
| 6/30/2022 | 0 | -15 | -17 | -17 | N/A |
| 3/31/2022 | 0 | -16 | -17 | -17 | N/A |
| 12/31/2021 | 0 | -16 | -19 | -19 | N/A |
| 9/30/2021 | 0 | -19 | -21 | -21 | N/A |
| 6/30/2021 | 0 | -22 | -22 | -22 | N/A |
| 3/31/2021 | 0 | -25 | -23 | -23 | N/A |
| 12/31/2020 | 0 | -25 | -23 | -23 | N/A |
| 9/30/2020 | 0 | -24 | -23 | -23 | N/A |
| 6/30/2020 | 0 | -23 | -21 | -21 | N/A |
| 3/31/2020 | 2 | -19 | -21 | -21 | N/A |
| 12/31/2019 | 2 | -22 | -21 | -21 | N/A |
| 9/30/2019 | 2 | -21 | -21 | -21 | N/A |
| 6/30/2019 | 2 | -22 | -24 | -24 | N/A |
| 3/31/2019 | 1 | -23 | -24 | -24 | N/A |
| 12/31/2018 | 1 | -21 | -23 | -23 | N/A |
| 9/30/2018 | 1 | -21 | -22 | -22 | N/A |
| 6/30/2018 | 1 | -23 | -22 | -22 | N/A |
| 3/31/2018 | 1 | -21 | N/A | -23 | N/A |
| 12/31/2017 | 1 | -24 | N/A | -24 | N/A |
| 9/30/2017 | 1 | -23 | N/A | -24 | N/A |
| 6/30/2017 | 2 | -18 | N/A | -19 | N/A |
| 3/31/2017 | 4 | -21 | N/A | -17 | N/A |
| 12/31/2016 | 6 | -20 | N/A | -16 | N/A |
| 9/30/2016 | 15 | -11 | N/A | -16 | N/A |
| 6/30/2016 | 15 | -15 | N/A | -22 | N/A |
| 3/31/2016 | 13 | -19 | N/A | -26 | N/A |
| 12/31/2015 | 11 | -24 | N/A | -31 | N/A |
| 9/30/2015 | 2 | -41 | N/A | -40 | N/A |
| 6/30/2015 | 0 | -50 | N/A | -46 | N/A |
| 3/31/2015 | 0 | -57 | N/A | -51 | N/A |
| 12/31/2014 | 1 | -64 | N/A | -58 | N/A |
| 9/30/2014 | 3 | -65 | N/A | -61 | N/A |
| 6/30/2014 | 4 | -71 | N/A | -62 | N/A |
| 3/31/2014 | 4 | -68 | N/A | -64 | N/A |
| 12/31/2013 | 5 | -65 | N/A | -61 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if 0T20's forecast earnings growth is above the savings rate (0.8%).
Bénéfices vs marché: Insufficient data to determine if 0T20's earnings are forecast to grow faster than the German market
Croissance élevée des bénéfices: Insufficient data to determine if 0T20's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 0T20's revenue (1% per year) is forecast to grow slower than the German market (5.5% per year).
Croissance élevée des revenus: 0T20's revenue (1% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if 0T20's Return on Equity is forecast to be high in 3 years time